This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.

Enchondromatosis (Ollier Disease / Maffucci Syndrome)내연골종증

📋 Contents and key points
ItemDetails
A. Classification codesICD-10: Q78.4 (enchondromatosis) | Special Copayment Reduction: V230 (rare disease)
B. SynonymsEnchondromatosis | Maffucci syndrome | Ollier disease
C. Adult onsetLikelihood of first onset in adulthood: moderate — enchondromas are usually detected in childhood, but mild lesions are sometimes found incidentally in adulthood; malignant transformation (chondrosarcoma) is the most important complication, occurring in adulthood (especially the 20s~40s), so continued follow-up of adult patients is essential; in Maffucci syndrome, hemangiomas and vascular complications also progress in adulthood.
1. History1899 Ollier (France) described multiple enchondromas → 1881 Maffucci reported a case of enchondromas + hemangiomas → 2011 Pansuriya et al. identified somatic mosaic IDH1/IDH2 mutations → turning point in understanding tumorigenesis.
2. CausesSomatic mosaic gain-of-function mutations in IDH1 (2q33.3) or IDH2 (15q26.1). Main variants: IDH1 R132C/H/S, IDH2 R172S/G. Somatic mutation in early embryonic development → clonal expansion of chondroblasts and vascular endothelial cells. No hereditary (germline) transmission. Non-hereditary disease.
3. GeneticsSomatic mosaic IDH1/IDH2 mutations (non-hereditary). Difficult to detect by peripheral blood DNA analysis; lesional tissue-based analysis needed. Timing of occurrence (early embryo) determines lesion extent. Ollier and Maffucci share the same IDH mutation spectrum. IDH1 R132C is the most common. IDH mutation → 2-HG overproduction → epigenetic abnormalities → blocked chondrocyte differentiation.
4. General epidemiologyPrevalence of Ollier disease about 1/100,000. Maffucci syndrome about 1/1,000,000 or less. About 3~5% of all enchondromas are enchondromatosis (multiple). Independent of sex and ethnicity. Unlike solitary enchondroma, the multiple form is enchondromatosis. Korean case reports exist.
5. PathophysiologyIDH1/IDH2 mutations → overproduction of 2-hydroxyglutarate (2-HG) → inhibition of TET2 and histone demethylases → DNA/histone hypermethylation (epigenetic abnormality) → block of terminal chondroblast differentiation → accumulation of immature cartilage matrix instead of mature cartilage (enchondroma formation). Hemangioma formation in vascular endothelial cells by the same mechanism (Maffucci). 2-HG itself promotes transformation to chondrosarcoma.
6. SymptomsBone: swelling of fingers and toes (enchondromas of small bones), limb deformity and shortening, fractures. Unilateral predominant distribution (Ollier disease). Maffucci: hemangiomas of skin and soft tissue (blue compressible masses), phleboliths, limb deformity. Malignant transformation: rapid growth of an existing lesion, increasing pain, soft tissue mass (signs of chondrosarcoma).
7. SignsX-ray: radiolucent lesions within the medullary cavity (unmineralized cartilage matrix), punctate calcification, bone expansion and cortical thinning. Unilateral predominant distribution. MRI: characteristic enchondroma signal (high T2 signal). Hemangioma: blue soft tissue mass that decreases with compression. Phleboliths opaque on X-ray. Soft tissue invasion on MRI with malignant transformation.
8. ScreeningNo screening of the general population (non-hereditary). After diagnosis, regular imaging follow-up (X-ray, MRI) is key to surveillance for malignant transformation. In Maffucci, assessment of the risk of intracranial hemangiomas and brain tumors (brain MRI). Confirmation by IDH1/IDH2 analysis of lesional tissue. Immediate MRI evaluation with acute symptom change (pain, mass growth).
9. DiagnosisClinical and imaging diagnosis: multiple enchondromas (medullary radiolucent lesions + punctate calcification, unilateral predominance) + hemangiomas (Maffucci). Confirmation: IDH1/IDH2 immunohistochemical staining of lesional tissue (IDH1 R132H antibody) or NGS. Differentiation of malignant transformation: MRI (soft tissue invasion, change in lesion size and matrix) + tissue biopsy. Serum 2-HG (research stage).
10. TreatmentAsymptomatic enchondroma: regular imaging follow-up. Symptomatic/deformity: curettage + bone grafting. Fracture: orthopedic fixation. Malignant transformation (chondrosarcoma): wide excision (+/- radiation, chemotherapy). IDH inhibitors (ivosidenib, enasidenib) under study. Maffucci hemangiomas: sclerotherapy, surgery. Management of vascular complications.
11. PrognosisOllier disease: lifetime risk of chondrosarcoma about 25~30%. Maffucci syndrome: higher risk of chondrosarcoma (about 30~50%), other malignancies (brain tumors, ovarian cancer, etc.) may also occur. Without malignant transformation, life expectancy is normal. Limb deformity and functional limitation reduce quality of life. Early detection by regular imaging follow-up is key to prognosis.
12. PreventionPrimary prevention not possible as a non-hereditary disease. Early detection of malignant transformation by regular imaging follow-up (MRI/X-ray every 6~12 months) is key. Immediate evaluation of symptom changes (increasing pain, mass growth). Limited use of radiation therapy (concern for malignant transformation). Recognition of warning signs through patient and clinician education.
13. ReferencesPansuriya TC, van Eijk R, d'Adamo P, et al. Somatic mosaic IDH1 and IDH2 mutations are associated with enchondromatosis. Nat Genet. 2011 … and 9 other papers

1. History

The history of enchondromatosis begins in the European medical literature of the late 19th century. In 1881, Antonio Maffucci of Italy reported a patient with combined enchondromas and soft tissue hemangiomas, and this unique clinical combination was later named "Maffucci syndrome." In 1899, Léopold Louis Xavier Édouard Ollier of France systematically described multiple enchondromas involving the long bones and defined them as an independent clinical entity, and the disease subsequently came to be called "Ollier disease."

In the first half of the 20th century, the clinical features and radiologic findings of enchondromas were established. Understanding accumulated regarding the clinical differences between solitary enchondroma and multiple enchondromatosis, the risk of malignant transformation (chondrosarcoma), and limb deformities and functional outcomes. The tendency of lesions in Ollier disease to be distributed predominantly on one side of the body and the prominence of multiple lesions in the small bones of the fingers and toes were described in clinical textbooks. In the 1960s~70s, long-term cohort data accumulated showing that the cumulative risk of malignant transformation to chondrosarcoma reaches about 25~30%.

The decisive turning point in understanding the molecular mechanism came in 2011, when Pansuriya et al. of the Netherlands identified somatic mosaic gain-of-function mutations in the IDH1 (isocitrate dehydrogenase 1) and IDH2 (isocitrate dehydrogenase 2) genes in lesional tissue from patients with Ollier disease and Maffucci syndrome. This discovery showed that IDH mutations found in leukemia, glioblastoma, etc. act by the same mechanism in skeletal tumors, and suggested that epigenetic abnormalities due to overproduction of 2-hydroxyglutarate (2-HG) are central to the development of enchondromatosis. IDH inhibitors (ivosidenib, enasidenib) were subsequently approved for IDH-mutant malignancies, and their potential application in enchondromatosis is being studied. To date, the standard first-line treatment is surgical curettage and bone grafting, and surveillance for malignant transformation through regular imaging follow-up has become central to clinical management.


2. Causes

The cause of enchondromatosis (Ollier disease and Maffucci syndrome) is somatic gain-of-function mutations in the IDH1 (2q33.3) or IDH2 (15q26.1) gene. IDH1 and IDH2 are enzymes that catalyze the oxidative decarboxylation of isocitrate to α-ketoglutarate (α-KG) in the cytoplasm and mitochondria, respectively.

Pathogenic mutations are mainly missense variants altering the Arg132 residue of IDH1 (R132C, R132H, R132S, etc.) or the Arg172 residue of IDH2 (R172S, R172G, etc.). These variants weaken the normal isocitrate oxidation reaction and instead promote an aberrant reaction that reduces α-KG to 2-hydroxyglutarate (2-HG). 2-HG is called an "oncometabolite" and inhibits α-KG-dependent dioxygenases (especially the TET2 DNA demethylase and JmjC histone demethylases), causing hypermethylation of DNA and histones. These epigenetic abnormalities block terminal differentiation of chondroblasts and maintain their proliferation, thereby forming enchondromas.

As with osteopetrosis, enchondromatosis is caused by somatic mosaic mutations. That is, a mutation arises in specific cells early in embryonic development and is passed on to their descendant cells (chondroblast clones, vascular endothelial cell clones), so only some cells in the body carry the mutation. Germline mutations have not been reported, so it is a non-hereditary disease that is not passed on to children. Phenotypic diversity (number and location of lesions, presence of hemangiomas) is determined by the embryonic stage at which the mutation arose and the tissues into which the mutant cell clone differentiates.

The IDH1 R132C variant is the most commonly reported in Ollier disease (about 35~40%), and IDH1/IDH2 mutations are also identified in Maffucci syndrome. However, some cases of enchondromatosis without an identified IDH mutation have also been reported, so other molecular mechanisms may be involved.


3. Genetics

Enchondromatosis is a non-hereditary disease caused by somatic mosaic mutations and is not passed from parents to children. The risk to siblings is also not increased. Therefore, genetic counseling in the traditional sense (estimating recurrence risk, carrier testing) does not apply, and clinical focus is on surveillance of the individual patient's natural course and management of the risk of malignant transformation.

The IDH1 gene is located on the long arm of chromosome 2 (2q33.3), and the IDH2 gene on the long arm of chromosome 15 (15q26.1). Both enzymes are part of the tricarboxylic acid cycle (TCA cycle) and catalyze the isocitrate → α-KG reaction. The mutant enzymes additionally carry out the α-KG → 2-HG reduction reaction, so intracellular 2-HG accumulates in excess by tens of times or more.

The molecular mechanisms of action of 2-HG are as follows. ① Inhibition of TET2 (DNA demethylase) → CpG hypermethylation → suppression of differentiation gene expression; ② inhibition of KDMs (histone demethylases, JmjC family) → increased H3K9me3 and H3K27me3 → chromatin condensation; ③ inhibition of EGLN (prolyl hydroxylases) → stabilization of HIF-1α → promotion of angiogenesis (contributing to hemangioma formation in Maffucci). These combined epigenetic abnormalities cause sustained chondroblast proliferation with suppressed terminal differentiation, and hemangioma formation by vascular endothelial cells.

Molecular diagnosis analyzes IDH1 R132 and IDH2 R172 variants in DNA obtained from lesional tissue (enchondroma or hemangioma). Immunohistochemical (IHC) staining with an anti-IDH1 R132H antibody is convenient and sensitive and is used as a diagnostic aid. ddPCR or amplicon NGS is used to detect variants in small amounts of lesional tissue. In most cases, the mutation is not detected by peripheral blood DNA analysis.


4. General epidemiology

Enchondromatosis (Ollier disease and Maffucci syndrome) is a rare disease; the prevalence of Ollier disease is estimated at about 1/100,000, and Maffucci syndrome is even rarer at 1/1,000,000 or less. Solitary enchondroma is much more common, accounting for about 10~20% of all bone tumors, but multiple enchondromatosis (Ollier/Maffucci) accounts for only about 3~5% of all enchondromas.

It occurs equally in males and females and is reported worldwide regardless of ethnicity or region. Because it is a non-hereditary disease caused by somatic mosaic mutations, familial occurrence is almost nonexistent and the risk of recurrence within the family is not increased. Lesions are often first detected in childhood, but mild forms are sometimes discovered incidentally in adults on radiologic examination.

In Ollier disease, enchondromas tend to be distributed predominantly on one side of the body, but bilateral distribution is not uncommon. The small bones of the fingers and toes, the long bones (femur, tibia, humerus), and the small bones of the sole of the foot are the most commonly involved sites. In Maffucci syndrome, hemangiomas of the skin and soft tissue (mainly venous) accompany the enchondromas.

The most important epidemiologic feature of patients with enchondromatosis is the risk of malignant transformation to chondrosarcoma. The lifetime risk of chondrosarcoma is reported to be about 25~30% in Ollier disease and higher, at 30~50%, in Maffucci syndrome. Malignant transformation occurs especially in adulthood (20s~40s), and the risk is high in large lesions of the pelvis, femur, and shoulder region. In Maffucci syndrome, in addition to chondrosarcoma, the risk of other malignancies is also increased, including brain tumors (glioblastoma, astrocytoma), ovarian cancer (mainly granulosa cell tumors), and pancreatic cancer.

In Korea, registration for rare disease Special Copayment Reduction (V230) is possible, and there are some domestic case reports. Collaboration of a multidisciplinary team (orthopedics, surgical oncology, radiology, genetics) for regular follow-up and surveillance for malignant transformation is important.


5. Pathophysiology

The core pathophysiology of enchondromatosis is 2-HG overproduction due to IDH1/IDH2 mutations and blocked chondroblast differentiation through epigenetic abnormalities.

In the normal growth plate, chondroblasts differentiate sequentially through the proliferating zone → hypertrophic zone → mineralizing zone. In this process, gene expression programs specific to each differentiation stage are coordinated epigenetically. 2-HG produced by IDH1/IDH2 mutations competitively inhibits the TET2 DNA demethylase and JmjC histone demethylases, suppressing expression of the genes that normally induce chondroblast hypertrophy and mineralization. As a result, chondroblasts remain in the proliferating zone, terminal differentiation and apoptosis are blocked, and immature cartilage cells and matrix accumulate within the medullary cavity. This is the histologic basis of enchondroma.

In Maffucci syndrome, the same IDH-mutant clone also differentiates into vascular endothelial cells, and HIF-1α hyperactivation by 2-HG (EGLN inhibition) continuously stimulates angiogenic signaling, forming venous hemangiomas. Phleboliths often form within the hemangiomas.

The molecular mechanism of malignant transformation (chondrosarcoma) has not been fully elucidated, but 2-HG itself tends to be overproduced even in IDH wild-type chondrosarcoma, and 2-HG is understood to directly stimulate cell proliferation signals and inhibit DNA damage repair, creating an environment in which additional somatic mutations (TP53, loss of CDKN2A/2B, RAS pathway variants, etc.) accumulate. Large lesions, involvement of the central skeleton such as the pelvis, ilium, and skull, and Maffucci syndrome (versus Ollier disease) are factors associated with a higher risk of malignant transformation.


6. Symptoms

The clinical symptoms of enchondromatosis vary depending on the location, number, and size of the lesions.

Symptoms of Ollier disease: The most common site of presentation is the small bones of the fingers and toes, where enchondromas form within the phalanges or metacarpals, causing finger swelling (short and thick) and deformity. Enchondromas within long bones cause limb shortening and bowing deformities, and in the lower limbs result in leg length discrepancy and gait abnormalities. When an enchondroma is located near the growth plate, growth disturbance is aggravated. The lesions themselves are usually painless, but pain becomes prominent when a fracture occurs or malignant transformation takes place. Low-energy pathologic fractures can occur in bones containing enchondromas, because the lesions weaken the cortical bone. The characteristic distribution pattern of Ollier disease is unilateral predominance, with a tendency for more lesions to occur in the right or left limbs.

Additional symptoms of Maffucci syndrome: In addition to the bone symptoms of Ollier disease, hemangiomas of the skin and soft tissue (mainly venous hemangiomas) are present. The hemangiomas are blue or purple soft tissue masses that shrink with compression and are most common on the hands, fingers, and forearms. Phleboliths form within the hemangiomas and appear as punctate opacities on X-ray. Rupture of hemangiomas or thrombus formation may rarely occur. In Maffucci syndrome, the risk of intracranial hemangiomas and vascular anomalies and of tumors of the ovary, pancreas, etc. is also increased.

Symptoms of malignant transformation: Rapid growth of a previously known enchondroma lesion, new or worsening pain, and appearance of a soft tissue mass are warning signs of malignant transformation to chondrosarcoma. When these symptoms appear, immediate MRI evaluation and tissue biopsy are needed. Chondrosarcoma usually arises as low grade (grade 1~2) and may become high grade as it progresses.


7. Signs

The physical and imaging signs of enchondromatosis are characteristic, as follows.

Physical signs: Enchondromas of the small bones of the fingers and toes are palpable as phalangeal swelling, with no or mild tenderness. Severe limb deformities (bowing, shortening, angular deformity) are visible. The hemangiomas of Maffucci syndrome are blue to purple soft tissue masses that characteristically decrease in size with compression. Abnormal motion or tenderness may be present at fracture sites. With malignant transformation, a rapidly growing, ill-defined mass appears, and pain is prominent.

Radiologic signs: On plain X-ray, enchondromas are radiolucent (lytic) lesions within the medullary cavity, with punctate or ring-like calcification (chondroid calcification) observed inside. As lesions enlarge, the cortical bone expands and thins, accompanied by bone deformity. Unilateral predominant distribution is characteristic. In Maffucci syndrome, phleboliths within soft tissue appear as round opacities on X-ray.

MRI signs: Enchondromas characteristically show intermediate signal on T1 and markedly high signal on T2 (high water content due to hyaline cartilage matrix). Internal septa (lobular pattern) and punctate low signal (calcification) are observed. With malignant transformation, increased T2 signal heterogeneity, cortical destruction, soft tissue invasion, and increased contrast enhancement appear. Soft tissue hemangiomas are identified as high signal on T2, and phleboliths as low-signal nodules.

Pathologic findings: On histologic examination, enchondromas show nodules of hyaline cartilage within the medullary cavity, with low cellularity and almost no nuclear atypia. In malignant transformation (chondrosarcoma), increased cellularity, nuclear atypia, binucleation, and cortical invasion are seen. Positive IDH1 R132H immunohistochemical staining is useful as a diagnostic aid.


8. Screening

Population-wide screening of the general population for enchondromatosis is not performed. Because it is a non-hereditary disease, family history-based screening also does not apply. After clinical diagnosis, regular imaging follow-up is the key to surveillance for malignant transformation.

Criteria for clinical suspicion: Enchondromatosis is suspected in the following situations. ① Multiple finger and toe swellings in children and adolescents; ② multiple intraosseous radiolucent lesions on X-ray (with punctate calcification); ③ progressive limb deformity and shortening; ④ enchondromas + blue compressible soft tissue masses (suspect Maffucci); ⑤ in adults, rapid growth of an existing intraosseous lesion or new pain.

Screening evaluation after initial diagnosis: When Ollier disease or Maffucci syndrome is diagnosed, whole-skeleton imaging (whole-body X-ray or whole-body MRI) or 99mTc bone scan is used to determine the full extent of lesions. In Maffucci syndrome, brain MRI is performed to assess the risk of intracranial vascular anomalies and brain tumors. Abdominal and pelvic MRI to assess the risk of visceral tumors such as ovarian and pancreatic cancer is included at diagnosis and in subsequent regular follow-up.

Regular surveillance for malignant transformation: There is no established standard surveillance protocol, but most specialized centers perform clinical evaluation and targeted imaging (MRI of high-risk sites) every 6~12 months. More frequent follow-up is recommended for high-risk sites (pelvic, femoral, and shoulder lesions, large lesions, Maffucci syndrome).

Immediate evaluation with symptom change: A sudden increase in pain at a lesion site, rapid mass growth, or appearance of a new soft tissue mass requires immediate MRI and tissue biopsy.


9. Diagnosis

The diagnosis of enchondromatosis is made by integrating clinical findings, radiologic imaging, tissue biopsy, and molecular genetic analysis.

Clinical diagnostic criteria: Ollier disease is diagnosed when multiple enchondromas (≥2 bone lesions) are identified on imaging. Maffucci syndrome is diagnosed when enchondromas are accompanied by soft tissue hemangiomas. Differentiation from solitary enchondroma is based on the number and distribution of lesions on imaging.

Radiologic imaging: X-ray identifies intraosseous radiolucent lesions, punctate calcification, bone expansion and deformity, and phleboliths. MRI (T1, T2, contrast enhancement) evaluates the exact extent of lesions, cortical integrity, soft tissue invasion, and the presence of malignant transformation. High T2 signal, intralesional septa, and punctate low signal (calcification) are characteristic of enchondroma. With malignant transformation, T2 heterogeneity, cortical destruction, a soft tissue mass, and irregular contrast enhancement appear. Whole-body MRI or 99mTc bone scan is used to determine the distribution of lesions throughout the body.

Tissue biopsy and pathology: When malignant transformation is suspected or the diagnosis is unclear at initial presentation, image-guided core needle biopsy or incisional biopsy is performed. Histologically, enchondroma is characterized by hyaline cartilage nodules, low cellularity, and almost no nuclear atypia. Chondrosarcoma shows increased cellularity, nuclear atypia, and cortical invasion. IDH mutations are confirmed by IDH1 R132H IHC or NGS.

Molecular genetic diagnosis: Variants in IDH1 exon 4 (codon 132) and IDH2 exon 4 (codon 172) are analyzed in lesional tissue DNA by ddPCR or amplicon NGS. IDH1 R132H IHC has high sensitivity and specificity and is useful as a screening test. Variants are mostly not detected in peripheral blood DNA. When evaluating malignant transformation, analysis of additional molecular alterations such as TP53, CDKN2A/2B, and KRAS is used as an adjunct for predicting prognosis.

Differentiation of malignant transformation: Distinguishing enchondroma from low-grade chondrosarcoma is clinically challenging. Lesion size of 5 cm or more, location in the deep skeleton (pelvis, shoulder, proximal femur), accompanying pain, and cortical destruction or a soft tissue mass on MRI are factors suggesting malignant chondrosarcoma. Final differentiation is made by tissue biopsy and pathologic findings.


10. Treatment

Treatment of enchondromatosis is individualized according to the presence of symptoms from the lesions, the degree of bone deformity, and the risk of malignant transformation.

Asymptomatic enchondroma — regular follow-up: Small enchondromas without symptoms or bone deformity are managed without surgery by regular imaging follow-up. Clinical evaluation and X-ray/MRI follow-up every 6~12 months monitor changes in lesion size and signs of malignant transformation.

Symptomatic enchondroma or bone deformity — curettage and bone grafting: When lesions cause pain, when bone deformity or shortening progresses, or when the risk of pathologic fracture is high, surgical curettage and bone grafting (autograft or allograft, or bone substitutes) are performed. In pediatric patients, lesions near the growth plate carry a risk of recurrence after growth is complete, so follow-up is needed. When there is limb length discrepancy, bone lengthening is considered.

Treatment of pathologic fractures: Fractures at enchondroma sites are treated with orthopedic fixation (metal plates, intramedullary nails), combined with curettage and bone grafting when needed.

Treatment of malignant transformation (chondrosarcoma): When chondrosarcoma is diagnosed, wide resection is the standard treatment. The resection margin is the most important factor determining prognosis. Chondrosarcoma responds poorly to conventional chemotherapy and radiation therapy, so complete surgical resection is the core of treatment. In high-grade chondrosarcoma or at unresectable sites, radiation therapy (carbon ion therapy, etc.) is used adjunctively, but its effect is limited.

IDH inhibitors (research stage): Ivosidenib (IDH1 inhibitor) and enasidenib (IDH2 inhibitor) have been approved for acute myeloid leukemia, and clinical trials evaluating their efficacy in IDH-mutant chondrosarcoma and enchondromatosis are underway. Induction of differentiation and antitumor effects are expected through suppression of 2-HG production.

Treatment of hemangiomas in Maffucci syndrome: When hemangiomas cause symptoms (pain, bleeding, cosmetic problems), sclerotherapy, laser treatment, or surgical excision is performed. Thrombosis due to phleboliths or rupture of hemangiomas requires immediate treatment.


11. Prognosis

The most important factor in the prognosis of enchondromatosis is whether malignant transformation (chondrosarcoma) occurs.

Risk of malignant transformation: In Ollier disease, the lifetime cumulative risk of chondrosarcoma is about 25~30%, markedly higher than in the general population. In Maffucci syndrome it is higher, at about 30~50%, and in addition to chondrosarcoma, the risks of brain tumors (glioblastoma, astrocytoma), ovarian granulosa cell tumors, pancreatic cancer, etc. are also increased. Malignant transformation usually occurs in adulthood (20s~40s), with a mean age at diagnosis of about 40 years when chondrosarcoma develops. Large lesions, involvement of the central skeleton such as the pelvis, shoulder, and skull, and Maffucci syndrome are high-risk factors.

Prognosis of chondrosarcoma: Enchondromatosis-related chondrosarcomas mostly arise as low to intermediate grade (grade 1~2) and have a relatively good prognosis, but the risk of local recurrence is high if wide resection is not achieved. High-grade (grade 3) chondrosarcoma carries a high risk of metastasis and has a poor prognosis. With appropriate surgical resection, 5-year survival is about 90% for low grade and about 40~60% for high grade.

Functional prognosis: Without malignant transformation, life expectancy is close to normal. When limb deformity and shortening are severe, functional limitation and reduced quality of life persist. Early corrective surgery in childhood (curettage, bone grafting, bone lengthening) contributes to long-term functional improvement. Early detection of malignant transformation through regular imaging follow-up is key to improving survival.

Importance of regular follow-up: Patients with enchondromatosis need lifelong regular clinical and imaging follow-up. Early detection of malignant transformation with MRI of high-risk sites every 6~12 months, annual whole-skeleton evaluation, and, in Maffucci syndrome, brain, abdominal, and pelvic MRI is decisive for prognosis.


12. Prevention

Enchondromatosis is a non-hereditary disease caused by somatic mosaic mutations, so primary prevention is not possible. Clinically important prevention is the early detection and treatment of malignant transformation.

Regular imaging follow-up — surveillance for malignant transformation: After an established diagnosis of enchondromatosis, regular clinical evaluation and imaging follow-up are key to surveillance for malignant transformation. Expert opinion recommends MRI follow-up every 6 months for high-risk lesions (large lesions of the pelvis, femur, shoulder, skull) and once a year for low-risk lesions (small lesions of the digits and long bones). A standard surveillance protocol has not yet been established, but a follow-up plan based on individual risk is determined by a multidisciplinary team.

Education on warning signs: Patients and families are educated about the warning signs of malignant transformation — rapid growth of an existing lesion, new or worsening pain, appearance of a new soft tissue mass — and are advised to visit a medical institution immediately if these signs occur.

Maffucci syndrome — surveillance for multiple malignancies: Because the risk of brain tumors, ovarian cancer, pancreatic cancer, etc. is high in addition to chondrosarcoma, patients with Maffucci syndrome receive comprehensive tumor surveillance, including regular brain MRI, abdominal and pelvic MRI, and gynecologic examinations.

Caution with radiation therapy: Radiation therapy for enchondroma or chondrosarcoma may increase the risk of radiation-induced sarcoma and requires caution. Use of radiation therapy is limited except for unresectable high-grade tumors or incomplete resection after surgery.

Lifestyle guidance: Patients are advised to limit high-risk trauma (contact sports, strenuous physical activity) at sites with a high risk of pathologic fracture. Regular low-impact exercise maintains muscle strength and function. Registration for rare disease Special Copayment Reduction (V230) and connection with patient support groups are used for medical cost support and information sharing.


13. References

  1. Pansuriya TC, van Eijk R, d'Adamo P, et al. Somatic mosaic IDH1 and IDH2 mutations are associated with enchondromatosis. Nat Genet. 2011;43(12):1256-1261. DOI: 10.1038/ng.1004. PMID: 22057234.

  2. Amary MF, Bacsi K, Maggiani F, et al. IDH1 and IDH2 mutations are frequent events in central chondrosarcoma and central and periosteal chondromas but not other mesenchymal tumours. J Pathol. 2011;224(3):334-343. DOI: 10.1002/path.2913. PMID: 21598255.

  3. Silve C, Jüppner H. Ollier disease. Orphanet J Rare Dis. 2006;1:37. DOI: 10.1186/1750-1172-1-37. PMID: 17010204.

  4. Verdegaal SH, Bovée JV, Pansuriya TC, et al. Incidence, predictive factors, and prognosis of chondrosarcoma in patients with Ollier disease and Maffucci syndrome: an international multicenter study of 161 patients. Oncologist. 2011;16(12):1771-1779. DOI: 10.1634/theoncologist.2011-0200. PMID: 22147011.

  5. Dürr HR, Lienemann A, Strauss A, Burgkart R, Mutschler W. Chondrosarcoma in Ollier's disease — a case report. Acta Orthop Scand. 1998;69(5):519-521. DOI: 10.3109/17453679808997782. PMID: 9855240.

  6. Liu J, Hudkins PG, Swee RG, Unni KK. Bone sarcomas associated with Ollier's disease. Cancer. 1987;59(7):1376-1385. DOI: 10.1002/1097-0142. PMID: 3815283.

  7. Mertens F, Unni KK. Enchondromatosis: Ollier disease and Maffucci syndrome. In: Fletcher CDM, Bridge JA, Hogendoorn PCW, Mertens F, eds. WHO Classification of Tumours of Soft Tissue and Bone. 4th ed. Lyon: IARC Press; 2013:271-272.

  8. Bhatt AA, Bhatt AB, Bhatt D. Maffucci syndrome: a rare case with brief review. J Cancer Res Ther. 2012;8(4):619-621. DOI: 10.4103/0973-1482.106583. PMID: 23271000.

  9. Bovée JV, Hogendoorn PC, Wunder JS, Alman BA. Cartilage tumours and bone development: molecular pathology and possible therapeutic targets. Nat Rev Cancer. 2010;10(7):481-488. DOI: 10.1038/nrc2869. PMID: 20535134.

  10. Cleven AH, Suijker J, Agrogiannis G, et al. IDH1 or -2 mutations do not predict outcome and do not cause loss of 5-hydroxymethylcytosine or altered histone modifications in central chondrosarcomas. Clin Sarcoma Res. 2012;2(1):8. DOI: 10.1186/2045-3329-2-8. PMID: 22738350.